Anastrozole Tablet
Product Images NDC 87063-224

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 87063-224). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Asclemed Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure For Anastrozole (Image 01)

Chemical structure of anastrozole, the active ingredient in Anastrozole Tablets 1 mg. The diagram shows the molecular formula representation with rings and labeled atoms, consistent with standard chemical notation for anastrozole.*

FDA Label Image

Figure 1 (Image 02)

A line graph depicting disease-free survival in months on the x-axis against the proportion of patients alive and disease-free on the y-axis. It compares two randomized treatments, anastrozole (dashed line) and tamoxifen (solid line), showing survival trends over approximately 90 months. The graph includes a table of the number of patients at risk for each treatment group at various time points.*

FDA Label Image

Figure 2 (Image 03)

A survival curve graph showing disease-free survival over 90 months for two treatments: anastrozole and tamoxifen. The y-axis represents the proportion alive and disease-free, and the x-axis shows time in months. The graph includes patient numbers at risk at various time points for both treatments.*

FDA Label Image

Figure 3 (Image 04)

A Kaplan-Meier survival curve graph comparing the proportion event-free over time (months) between two randomized treatments for Anastrozole 1 mg tablets versus Tamoxifen. The graph shows time to event up to 120 months with corresponding numbers of patients at risk listed below the x-axis for each treatment group.*

FDA Label Image

Figure 4 (Image 05)

A Kaplan-Meier survival curve chart comparing the proportion of patients event-free over time (in months) for two randomized treatments: Anastrozole (solid line) and Tamoxifen (dashed line). The chart includes a table showing the number of patients at risk at various month intervals up to 120 months. The vertical axis represents the proportion event-free, ranging from 0.50 to 1.00.*

FDA Label Image

Figure 5 (Image 06)

A Kaplan-Meier survival curve graph comparing time to progression in months between two randomized treatments: Anastrozole and Tamoxifen. The y-axis shows the proportion not progressing, while the x-axis displays time in months. A legend differentiates the two treatment groups by solid and dashed lines.*

FDA Label Image

Figure 6 (Image 07)

A Kaplan-Meier survival curve showing the proportion of patients not progressing over time in months, comparing randomized treatments of Anastrozole and Tamoxifen. The x-axis represents time to progression in months, and the y-axis shows the proportion not progressing. Patient numbers at risk are listed below the graph for each time point.*

FDA Label Image

Label (Label)

Multiple packaging labels of Anastrozole Tablets USP 1 mg by Enovachem Pharmaceuticals, relabeled for Asclemed USA Inc. Each label displays NDC codes (87063-224-30, 87063-224-90, 87063-224-60, 87063-224-05) and respective quantities of 30, 90, 60, and 500 tablets. Labels include manufacturing and storage information, a QR code, and warnings about prescription dispensing.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.